Tucidinosta (Epidaza (approved in China), Not yet branded in other markets)
Kinase Inhibitor
Description
Tucidinostat (also known as chidamide) is a selective histone deacetylase (HDAC) inhibitor that has been studied in combination therapy for microsatellite stable (MSS) colorectal cancer. This epigenetic modulator is used alongside PD-1/PD-L1 inhibitors and anti-angiogenic agents to enhance immune response in MSS colorectal tumors, which typically show poor response to immunotherapy alone. The drug works by modifying chromatin structure to potentially increase tumor immunogenicity and improve outcomes in this challenging patient population.
Mechanism of Action
Tucidinostat selectively inhibits class I histone deacetylases (HDAC1, HDAC2, HDAC3) and class IIb HDAC10, leading to increased histone acetylation and altered gene expression patterns. This epigenetic modification can enhance tumor antigen presentation, increase immune cell infiltration, and potentially overcome immune resistance mechanisms commonly seen in MSS colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Epidaza (approved in China), Not yet branded in other markets |
| Category | Kinase Inhibitor |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.